资讯

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...
The scientists at the University of California, San Francisco, and Johns Hopkins University in Baltimore injected an ...
A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...
A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...
Searching for stability, the nanofibers bonded to amyloid-beta proteins, a key culprit implicated in Alzheimer’s disease. But ...
Scientists have developed a new test for a biomarker in brain tissue that could detect people who will go on to develop motor neuron disease ... looks for specific protein clumps in brain tissue ...
The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...
Imagine if this fountain of youth wasn’t actually hidden in some mythical place; rather, it resided in tiny factories abiding ...
They then compared the protein binding partners of SOD1 trimers ... notion that muscle wasting in ALS is a secondary result of motor neuron degeneration—when these neurons don't function ...